Women's Health

PMDD: Symptoms, Diagnosis, and Treatment Options

A guide to premenstrual dysphoric disorder — severe mood and physical symptoms tied to the menstrual cycle, how it differs from PMS, and evidence-based treatment options.

9 min read

Intro

Premenstrual dysphoric disorder (PMDD) is a severe, cyclical mood disorder tied to the menstrual cycle. It causes significant emotional and physical symptoms — predominantly mood-related — in the week or two before menstruation (the luteal phase), which resolve within a few days of the period beginning.

PMDD is distinct from ordinary premenstrual syndrome (PMS) by the severity of its symptoms and their impact on daily functioning, relationships, and quality of life. It is a formal psychiatric diagnosis (DSM-5) and affects an estimated 2–6% of people who menstruate. Despite causing significant distress, it remains underdiagnosed — often dismissed as “bad PMS” or attributed to stress or personality. Effective treatments exist, and most people with PMDD see substantial symptom relief with appropriate management.

Key Points

  • PMDD causes severe mood symptoms — depression, anxiety, irritability, or sudden mood swings — in the luteal phase, resolving within days of menstruation starting.
  • PMDD is not the same as PMS; it is diagnosed only when symptoms are severe enough to impair daily functioning.
  • The underlying mechanism is abnormal sensitivity to normal hormonal fluctuations — not abnormal hormone levels.
  • Symptom tracking over at least two cycles with a validated tool is essential for diagnosis.
  • SSRIs are the first-line evidence-based treatment; they can be taken continuously or only in the luteal phase.
  • Suicidal thoughts during the luteal phase are recognised in severe PMDD and require urgent help.

Background

The menstrual cycle is divided into two main phases: the follicular phase (from menstruation to ovulation) and the luteal phase (from ovulation to the start of the next period). In PMDD, symptoms begin in the luteal phase — typically 1–2 weeks before menstruation — and resolve within a few days of the period starting. This predictable, cyclical pattern is the hallmark of PMDD.

People with PMDD typically have a clear window of symptom-free or near-symptom-free days after their period ends and after ovulation has not yet occurred. This distinguishes PMDD from other depressive or anxiety disorders, which do not cycle with menstruation (though they may worsen premenstrually).

PMDD was formally recognised as a psychiatric diagnosis in DSM-5 (2013) and is listed in ICD-11. This recognition is important because it validates patients’ experiences and opens pathways to appropriate treatment.

Causes or Mechanisms

The exact mechanism of PMDD is not fully understood, but current evidence points to abnormal neurological sensitivity to normal hormonal fluctuations — particularly to changes in progesterone and its active metabolites.

During the luteal phase, progesterone levels rise and fall. One metabolite — allopregnanolone — acts on GABA-A receptors in the brain, normally producing a calming effect. In PMDD, the brain appears to respond differently to these fluctuations, triggering dysphoric symptoms rather than maintaining stability.

Key findings:

  • Progesterone and oestrogen levels in people with PMDD are generally similar to those in unaffected women — the problem is sensitivity, not hormone levels.
  • Eliminating the hormonal cycle with GnRH agonists suppresses PMDD symptoms, confirming the hormonal trigger.
  • Re-adding back oestrogen or progesterone to people with PMDD who have had their cycle suppressed can re-trigger symptoms, while unaffected people remain well.
  • Serotonin pathways are also involved, explaining why SSRIs are effective.

Risk factors include:

  • Personal or family history of depression, anxiety, or PTSD
  • History of postpartum depression (shared biological vulnerabilities)
  • Trauma history
  • Approaching perimenopause, when hormonal fluctuations increase

Diagnosis

There is no blood test or scan for PMDD. Diagnosis requires:

  1. Prospective symptom tracking for at least two menstrual cycles using a validated tool such as the Daily Record of Severity of Problems (DRSP) or the Calendar of Premenstrual Experiences (COPE). Retrospective reporting alone is insufficient — many people misremember the timing or severity of symptoms.

  2. DSM-5 criteria: at least five symptoms from the defined list, including at least one core mood symptom:

    • Marked affective lability (mood swings)
    • Marked irritability or anger
    • Marked depression, hopelessness, or self-deprecating thoughts
    • Marked anxiety or tension

    Plus one or more additional symptoms:

    • Decreased interest in usual activities
    • Difficulty concentrating
    • Fatigue or low energy
    • Appetite changes or food cravings
    • Sleep disturbance (insomnia or hypersomnia)
    • Feeling overwhelmed or out of control
    • Physical symptoms (breast tenderness, bloating, joint or muscle pain)

  3. Timing: symptoms occur only in the luteal phase and resolve within a few days of menstruation starting.

  4. Exclusion of premenstrual exacerbation: PMDD should not be a worsening of an underlying condition (e.g., depression, bipolar disorder, anxiety disorder) where effective underlying treatment resolves the premenstrual pattern.

Who to see

Start with your GP, who can guide symptom tracking, exclude other conditions, and initiate first-line treatment. If symptoms are complex — co-occurring depression, a history of postpartum depression, or diagnostic uncertainty — referral to a gynaecologist, psychiatrist, or specialist PMDD clinic is appropriate.

Treatment

SSRIs (first-line)

Selective serotonin reuptake inhibitors (SSRIs) are the most evidence-based treatment for PMDD. Unlike their role in depression — where full effect takes several weeks — SSRIs appear to work more rapidly in PMDD, which is why intermittent dosing is effective.

  • Continuous dosing: taken every day throughout the cycle. Suitable for those who also have underlying depression or who prefer not to track luteal timing.
  • Luteal-phase dosing: taken for approximately 14 days before the expected period and stopped when menstruation begins. Reduces overall medication exposure and is equally effective for many people.
  • Semi-intermittent dosing: standard daily dose plus an increase during the luteal phase.

SSRIs used for PMDD include fluoxetine (which has the most evidence), sertraline, paroxetine, citalopram, and escitalopram. Common side effects include nausea, sleep changes, and sexual dysfunction — most manageable and often reduced with luteal-phase dosing.

Hormonal approaches

For those who do not respond to SSRIs or prefer a hormonal approach:

  • Combined oral contraceptives: drospirenone-containing pills (e.g., Yaz/Yasmin) have the strongest evidence. By suppressing ovulation, they eliminate the luteal-phase hormonal shift. Other pill formulations have less consistent evidence.
  • GnRH agonists (e.g., leuprorelin, goserelin): suppress ovarian function entirely, creating a temporary, reversible menopause. Highly effective — over 90% of people respond — but associated with significant side effects (menopausal symptoms, bone density loss). Reserved for severe or refractory cases; usually combined with add-back oestrogen to reduce side effects.
  • Progestogen-only methods: some people with PMDD find progestogen-only contraception worsens symptoms, as progestogen can trigger luteal-phase-like responses — although individual responses vary.

Psychological approaches

  • Cognitive behavioural therapy (CBT): evidence supports reduction in PMDD symptom severity and improved coping, particularly for emotional symptoms.
  • Mindfulness-based approaches: emerging evidence as an adjunct for reducing symptom burden.

Lifestyle

  • Regular aerobic exercise: evidence supports improvement in mood regulation and reduction in premenstrual symptom severity.
  • Dietary adjustments: some evidence supports reducing caffeine, alcohol, and refined carbohydrates in the luteal phase; calcium supplementation (1,200 mg/day) has modest evidence.
  • Sleep regularity: disrupted sleep worsens mood dysregulation; good sleep hygiene is supportive.

Surgical option

In severe, refractory cases, bilateral salpingo-oophorectomy (removal of both ovaries) is curative but permanent, causing surgical menopause. This is only considered after all other treatments have failed, following extensive specialist review.

When to Seek Urgent Help

PMDD can cause severe depression and, in some people, suicidal thoughts or self-harm — particularly in the days immediately before menstruation.

Seek emergency help immediately if you or someone with PMDD:

  • Is having thoughts of suicide or self-harm
  • Feels unable to keep themselves safe
  • Is in acute psychological crisis

Contact emergency services or go to an emergency department. PMDD does not reduce the seriousness of suicidal thinking — it requires urgent assessment.

Crisis lines:

  • US: Call or text 988 (Suicide & Crisis Lifeline)
  • UK: Call 116 123 (Samaritans)
  • Australia: Call 13 11 14 (Lifeline)

Risks, Benefits, and Prognosis

Untreated PMDD causes significant cumulative impairment — affecting work, relationships, parenting, and overall quality of life. Many people experience shame or self-blame before receiving a diagnosis.

With appropriate treatment:

  • SSRIs are effective in 60–70% of people, often with rapid response
  • GnRH agonists are effective in over 90% of people
  • Quality of life improves substantially for most people with treatment

PMDD typically worsens during the perimenopause as hormonal fluctuations become more irregular and pronounced. For most people, symptoms resolve permanently after menopause. Managing the perimenopausal transition carefully — sometimes with HRT — is important for people with PMDD approaching this stage.

FAQ

Q: Can PMDD cause suicidal thoughts? A: Yes. Severe depression and suicidal ideation in the luteal phase are recognised features of PMDD in its most severe forms. These are real and serious — not “just hormones.” If you are experiencing them, please reach out for emergency support. PMDD is treatable, and these episodes can be prevented with appropriate care.

Q: Does the pill help PMDD? A: It depends on the pill. Combined oral contraceptives containing drospirenone (e.g., Yaz, Yasmin) have the best evidence. Other pills have more variable effects — some people find relief, others do not, and progestogen-only methods sometimes worsen symptoms. Response is highly individual and may require trying more than one formulation.

Q: If I have PMDD, am I more likely to have postnatal depression? A: Yes. PMDD and postpartum depression appear to share underlying neurobiological vulnerabilities related to sensitivity to hormonal fluctuations. Having PMDD is a significant risk factor for postpartum depression, and vice versa. Informing your obstetric team of a PMDD history allows for appropriate monitoring and support planning.

Q: Can lifestyle changes cure PMDD? A: Lifestyle changes can help reduce severity but are not sufficient alone for most people with true PMDD. They work best as adjuncts to evidence-based treatments such as SSRIs.

Q: Does PMDD go away at menopause? A: For most people, yes. PMDD is driven by cyclical hormonal fluctuations, and once menopause is established, the condition typically resolves. However, the perimenopause — the transition leading up to menopause — can involve worsening PMDD symptoms as fluctuations become more pronounced before stabilising.

Further Reading